CN106031725B - 荷叶碱和其类似物的药物应用 - Google Patents
荷叶碱和其类似物的药物应用 Download PDFInfo
- Publication number
- CN106031725B CN106031725B CN201610333841.3A CN201610333841A CN106031725B CN 106031725 B CN106031725 B CN 106031725B CN 201610333841 A CN201610333841 A CN 201610333841A CN 106031725 B CN106031725 B CN 106031725B
- Authority
- CN
- China
- Prior art keywords
- nuciferine
- analog
- medicine
- application
- weight ratio
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
组别 | 正常组 | 模型组 | 药物组1 | 药物组2 | 药物组3 |
尿酸含量(μmol/L) | 127 | 171 | 116 | 133 | 118 |
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610333841.3A CN106031725B (zh) | 2016-05-18 | 2016-05-18 | 荷叶碱和其类似物的药物应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610333841.3A CN106031725B (zh) | 2016-05-18 | 2016-05-18 | 荷叶碱和其类似物的药物应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106031725A CN106031725A (zh) | 2016-10-19 |
CN106031725B true CN106031725B (zh) | 2017-03-08 |
Family
ID=57149317
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610333841.3A Active CN106031725B (zh) | 2016-05-18 | 2016-05-18 | 荷叶碱和其类似物的药物应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106031725B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102057226B1 (ko) * | 2018-03-09 | 2019-12-18 | 코스맥스엔에스 주식회사 | 연잎 추출물을 포함하는 근기능 및 운동능 강화 기능성 식품 조성물 및 그 제조방법 |
CN110664741B (zh) * | 2019-10-13 | 2021-07-06 | 中国计量大学 | 提高荷叶碱生物利用度的荷叶碱溶液的制备方法 |
CN114751860B (zh) * | 2022-03-22 | 2024-03-15 | 华侨大学 | 一种荷叶碱或其衍生物的合成方法以及荷叶碱衍生物及其应用 |
CN115444893B (zh) * | 2022-09-02 | 2023-07-07 | 陕西中药研究所(陕西医药信息中心) | 一种降尿酸活性物质组合物及其应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7799802B2 (en) * | 2004-08-03 | 2010-09-21 | Institstute of Oriental Medical Science Inc. | Method and health food for preventing and/or alleviating psychiatric disorder, and/or for effectuating sedation |
CN101085041B (zh) * | 2007-07-11 | 2010-11-10 | 石任兵 | 荷叶总生物碱提取物及其制备方法 |
-
2016
- 2016-05-18 CN CN201610333841.3A patent/CN106031725B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN106031725A (zh) | 2016-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106031725B (zh) | 荷叶碱和其类似物的药物应用 | |
US20170266213A1 (en) | Use of beta-nicotinamide mononucleotide in preparation of anti-aging drugs or health-care products | |
KR101706624B1 (ko) | 고병원성 감염성 질환의 예방 및 치료제 | |
AU2014261329A1 (en) | Fenfluramine for use in the treatment of dravet syndrome | |
WO2022017304A1 (zh) | 大麻二酚在治疗冠状病毒感染中的应用 | |
CN108721281A (zh) | 新的抗病毒药物及其应用 | |
CN103432184B (zh) | 牛蒡子提取物在制药或食品中的应用 | |
EP3804718A1 (en) | Use of 2,3,5-substituted thiophene compound to prevent, ameliorate, or treat breast cancers | |
EP3773731A1 (en) | Pharmaceutical formulations | |
US20230077704A1 (en) | Application of nitazoxanide and active form thereof, tizoxanide, in treatment of sars-cov-2 infection | |
CN1833644B (zh) | 青蒿素及其衍生物二氢青蒿素、蒿甲醚、蒿乙醚、青蒿琥酯在制药中的应用 | |
EP3263114A1 (en) | Use of albiflorin or pharmaceutically acceptable salt for prevention and/or treatment of irritable bowel syndrome | |
CN102459245B (zh) | 用于治疗感染性疾病的噻吨衍生物 | |
CN104623671B (zh) | 含有乙酰胆碱酯酶抑制剂和二甲双胍的复方药用组合物 | |
JP5553168B2 (ja) | 脳機能低下の改善剤 | |
CN106038534A (zh) | 冬凌草甲素在制备抗抑郁症药物中的用途 | |
US9629866B2 (en) | Use of cordycepin in manufacture of medicaments for anti-depression | |
AU2018255954A1 (en) | Combination therapy for use in treating retroviral infections | |
EP3782620B1 (en) | Pharmaceutical composition comprising 1,2-naphthoquinone derivative for use in preventing or treating acute myeloid or lymphoblastic leukemia | |
CN106038522A (zh) | 大黄酸在制备抗抑郁症药物中的用途 | |
CN102319260A (zh) | 顺铂联合伊曲康唑异构体在制备治疗肺癌药物中的应用 | |
CN106822152B (zh) | 一种药物组合物及其应用 | |
CN109846876B (zh) | 木脂素类化合物在抗肿瘤中的应用及其药物制备 | |
EP4115883A1 (en) | Use of 2,3,5-substituted thiophene compound for preventing, ameliorating, or treating ovarian cancer | |
CN112154151A (zh) | 治疗或预防冠状病毒科感染 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Drug application of nuciferine and analogue thereof Effective date of registration: 20190725 Granted publication date: 20170308 Pledgee: Bank of China, Limited by Share Ltd, Guangzhou, Panyu branch Pledgor: Qifang Pharmaceutical Co., Ltd., Guangdong Province Registration number: 2019440000276 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20220223 Granted publication date: 20170308 Pledgee: Bank of China Limited by Share Ltd. Guangzhou Panyu branch Pledgor: GUANGDONG QIFANG MEDICINES Co.,Ltd. Registration number: 2019440000276 |